Multiple Myeloma

Patrick DalyOncology | October 3, 2022
In the IKEMA trial, researchers compared carfilzomib and dexamethasone plus isatuximab against carfilzomib and ...
Read More
DocWire News EditorsOncology | December 23, 2021
In Docwire News’ roundtable series discussing research presented at ASH 2021, moderator Dr. Saad Usmani is joined by ...
DocWire News EditorsOncology | December 20, 2021
Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, looks into the future of ...
DocWire News EditorsOncology | December 20, 2021
Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, discusses the safety and ...
DocWire News EditorsOncology | December 20, 2021
Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, describes the new ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | December 16, 2021
The bispecific antibody teclistamab displayed a manageable safety profile at the recommended phase II dose and continued ...
DocWire News EditorsOncology | December 16, 2021
Whole–body diffusion–weighted imaging (WB-DWI) is used for evaluating patients with newly diagnosed multiple myeloma ...
DocWire News EditorsOncology | December 16, 2021
In a study, published in Hematological Oncology, researchers examined the demographic characteristics, pathological ...
DocWire News EditorsOncology | December 16, 2021
Bortezomib is a proven treatment for patients with multiple myeloma (MM), however, some patients achieve suboptimal ...
DocWire News EditorsOncology | December 16, 2021
According to Szabolcs Kiss, MD, and colleagues, the most optimal first–line treatment regimen for patients with newly ...
DocWire News EditorsOncology | December 15, 2021
Shaji Kumar, MD, a myeloma specialist from Mayo Clinic in Rochester, Minnesota, reviews recent updates in late-phase ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | December 13, 2021
According to findings presented at the 2021 ASH Annual Meeting, the combination of daratumumab, carfilzomib, ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | December 13, 2021
Findings from phase II of the phase I/II MajesTEC-1 study on teclistamab were presented for the first time at the 2021 ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | December 10, 2021
A study reported updated results from the CARTITUDE-1 trial, which previously showed that cilacabtagene autoleucel ...
DocWire News EditorsOncology | December 10, 2021
Shaji Kumar, MD, a myeloma specialist from Mayo Clinic in Rochester, Minnesota, discusses the upcoming changes in the ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | December 10, 2021
The combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell ...
Rebecca AraujoASH Annual Meeting and Exposition 2021 | December 9, 2021
In a phase I trial, the B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor (CAR) T-cell therapy ...
DocWire News EditorsOncology | December 3, 2021
A recent study, led by Gabriel Tremblay, analyzed data from STORM—a phase IIb clinical trial on selinexor and low dose ...
DocWire News EditorsOncology | December 3, 2021
A phase III clinical trial compared treatment with daratumumab, dexamethasone, and lenalidomide against dexamethasone ...
DocWire News EditorsOncology | December 3, 2021
A meta-analysis, conducted by Wu Ye and collaborators from the Department of Hematology at the West China Hospital, ...
Advertisement
Advertisement
Latest News

December 1, 2023